94.15
price up icon0.51%   0.48
 
loading
Merus N V stock is traded at $94.15, with a volume of 13.74M. It is up +0.51% in the last 24 hours and up +43.00% over the past month. Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$93.67
Open:
$93.62
24h Volume:
13.74M
Relative Volume:
9.90
Market Cap:
$7.12B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-23.84
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+38.01%
1M Performance:
+43.00%
6M Performance:
+123.69%
1Y Performance:
+88.45%
1-Day Range:
Value
$93.52
$94.30
1-Week Range:
Value
$66.13
$94.56
52-Week Range:
Value
$33.19
$94.56

Merus N V Stock (MRUS) Company Profile

Name
Name
Merus N V
Name
Phone
31 030 253 8800
Name
Address
YALELAAN 62, 3584 CM UTRECHT
Name
Employee
260
Name
Twitter
@MerusNV
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
MRUS's Discussions on Twitter

Compare MRUS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MRUS
Merus N V
94.15 7.10B 35.93M -244.56M -157.31M -3.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Merus N V Stock (MRUS) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-17-25 Initiated Barclays Overweight
Aug-25-25 Initiated Alliance Global Partners Buy
Feb-13-25 Initiated Piper Sandler Overweight
Feb-07-25 Initiated Wells Fargo Overweight
Nov-21-24 Initiated Goldman Buy
Oct-24-24 Initiated UBS Buy
Mar-28-24 Initiated Truist Buy
Mar-04-24 Reiterated Needham Buy
Nov-02-23 Initiated Canaccord Genuity Buy
Aug-21-23 Initiated TD Cowen Outperform
Aug-02-22 Initiated Stifel Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Feb-10-22 Initiated Needham Buy
Nov-17-21 Resumed Guggenheim Buy
Jun-07-21 Upgrade Citigroup Neutral → Buy
Apr-08-21 Initiated William Blair Outperform
Mar-16-21 Initiated SVB Leerink Outperform
Jun-26-20 Initiated H.C. Wainwright Buy
May-27-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-20-19 Resumed Guggenheim Buy
Jun-28-19 Initiated ROTH Capital Buy
Apr-12-19 Resumed Guggenheim Buy
Apr-03-19 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-27-19 Initiated Berenberg Buy
Jan-02-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-15-17 Initiated RBC Capital Mkts Outperform
Mar-21-17 Downgrade Citigroup Buy → Neutral
Dec-22-16 Upgrade Citigroup Neutral → Buy
Nov-07-16 Downgrade Citigroup Buy → Neutral
Jun-13-16 Initiated Citigroup Buy
Jun-13-16 Initiated Guggenheim Buy
Jun-13-16 Initiated Wedbush Outperform
View All

Merus N V Stock (MRUS) Latest News

pulisher
Sep 30, 2025

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V.MRUS - The AI Journal

Sep 30, 2025
pulisher
Sep 30, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS) - PR Newswire

Sep 30, 2025
pulisher
Sep 30, 2025

Latham & Watkins Advises Merus in US$8 Billion Acquisition by Genmab - Latham & Watkins LLP

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab Nears Deal to Buy Cancer Drugmaker Merus - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Sep 30, 2025
pulisher
Sep 30, 2025

MRUS Analyst Rating Update: Guggenheim Downgrades to Neutral | M - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

MRUS Analyst Rating Update: Canaccord Genuity Adjusts PT and Rat - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (MRUS) Sees Rating Downgrade and Target Price Raise by Wells Fargo | MRUS Stock News - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (MRUS) Receives Rating Downgrade by LifeSci Capital | MRUS Stock News - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Barclays Downgrades MRUS, Lowers Price Target Amid Market Adjustments | MRUS Stock News - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (MRUS) Sees Downgrade from UBS with Raised Price Target | MRUS Stock News - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (NASDAQ:MRUS) Receives "Market Perform" Rating from Lifesci Capital - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Barclays Downgrades Merus to Equalweight From Overweight, Adjusts Price Target to $97 From $112 - MarketScreener

Sep 30, 2025
pulisher
Sep 30, 2025

BMO Capital Downgrades Merus to Market Perform From Outperform, Adjusts Price Target to $97 From $110 - MarketScreener

Sep 30, 2025
pulisher
Sep 30, 2025

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal - Stocktwits

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (NASDAQ:MRUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab Bets Big On Cancer With $8 Billion Merus Deal - Finimize

Sep 30, 2025
pulisher
Sep 30, 2025

Merus Reaches Analyst Target Price - Nasdaq

Sep 30, 2025
pulisher
Sep 30, 2025

How big funds are accumulating Merus N.V. (2GH) stock2025 Sector Review & Proven Capital Preservation Methods - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

MRUS Stock Downgraded: HC Wainwright & Co. Lowers Price Target | - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab to acquire Merus shares for $8bn - Yahoo Finance

Sep 30, 2025
pulisher
Sep 30, 2025

Barclays downgrades Merus stock to Equalweight, cuts price target on valuation - Investing.com

Sep 30, 2025
pulisher
Sep 30, 2025

Guggenheim downgrades Merus stock to Neutral following Genmab acquisition - Investing.com

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - AD HOC NEWS

Sep 30, 2025
pulisher
Sep 30, 2025

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction - Yahoo Finance

Sep 30, 2025
pulisher
Sep 30, 2025

EQT Is Shareholder in Merus, Acquired by Denmark's Genmab - MarketScreener

Sep 30, 2025
pulisher
Sep 30, 2025

Merus stock rating downgraded by UBS after Genmab acquisition - Investing.com India

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab to acquire Merus for $8 billion in cash deal By Investing.com - Investing.com Australia

Sep 30, 2025
pulisher
Sep 30, 2025

What’s the recovery path for long term holders of Merus N.V.Market Volume Report & Smart Money Movement Alerts - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Is Merus N.V. building a consolidation base2025 Winners & Losers & High Win Rate Trade Tips - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab to acquire Merus for $8 billion in cash deal - Investing.com

Sep 30, 2025
pulisher
Sep 29, 2025

Genmab swallows Merus in US$8bn deal - European Biotechnology Magazine

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab adding late-stage bispecific in $8B Merus acquisition - BioWorld MedTech

Sep 29, 2025
pulisher
Sep 29, 2025

Mid Cap Stocks To ConsiderSeptember 29th - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Will Merus N.V. stock see PE expansionLong Setup & Risk Adjusted Swing Trade Ideas - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Merus N.V. Stock: Analyzing Recent Fluctuations - timothysykes.com

Sep 29, 2025
pulisher
Sep 29, 2025

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes - FinancialContent

Sep 29, 2025
pulisher
Sep 29, 2025

Leadership Changes and Bold Moves Shake Global Drugmakers - Devdiscourse

Sep 29, 2025
pulisher
Sep 29, 2025

Merus (MRUS) Experiences Surge with Significant Stock Price Incr - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab’s $8B Merus takeout is latest push toward full ownership of programs - biocentury.com

Sep 29, 2025
pulisher
Sep 29, 2025

Can Merus Sustain The Leap? - StocksToTrade

Sep 29, 2025
pulisher
Sep 29, 2025

Transcript : Genmab A/S, Merus N.V.M&A Call - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

MRUS: Truist Securities Downgrades Rating, Raises Price Target | MRUS Stock News - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

Promising Medical Stocks To Keep An Eye OnSeptember 29th - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab to Acquire Merus in $8 Billion Biotech Deal - USA Herald

Sep 29, 2025
pulisher
Sep 29, 2025

MRUS Shares Surge Amid Acquisition Talks - timothysykes.com

Sep 29, 2025
pulisher
Sep 29, 2025

4 Firms Advise On Genmab's $8B Merus Acquisition Plan - Law360

Sep 29, 2025
pulisher
Sep 29, 2025

HC Wainwright Downgrades Merus to Neutral From Buy, Price Target at $97 - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders - Benzinga

Sep 29, 2025
pulisher
Sep 29, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Sep 29, 2025
pulisher
Sep 29, 2025

A&O Shearman advises Genmab on its proposed USD8 billion acquisition of Merus - A&O Shearman

Sep 29, 2025

Merus N V Stock (MRUS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
Cap:     |  Volume (24h):